# RENAL PHARMACOLOGY SUMMARY

*High-Yield Concept Retrieval Sheets*

| | | | |
|---|---|---|---|
| **System:** | Renal Pharmacology Module | **Target Drug Class:** | Carbonic Anhydrase Inhibitors |
| **Format Theme:** | Active Recall & Core Concept Counters | **Review Status:** | Final Approved Summary Block |

## 3. Carbonic Anhydrase Inhibitors

Total: [5] Concepts

### KEY AGENTS & OVERVIEW [1]

- **1. Representative Drugs:** Includes **Acetazolamide**, **Dichlorophenamide**, and **Methazolamide**.

### MECHANISM OF ACTION (MOA) [1]

- **1. Proximal Carbonic Anhydrase Inhibition:** These agents directly inhibit the carbonic anhydrase enzyme within the brush border and cytoplasm of the **proximal convoluted tubule (PCT)**; this halts the reabsorption of luminal bicarbonate, causing $HCOO_3^-$ to accumulate inside the tubule where it osmotically draws water along with it to yield diuresis.

### ACTIVE RECALL & PHARMACOKINETIC DYNAMICS [3]

- **1. Why do patients rapidly develop pharmacological tolerance to these drugs?**
  *Explanation:* When bicarbonate reabsorption is blocked in the PCT, the downstream distal nephron segments initiate a compensatory mechanism by significantly increasing **NaCl reabsorption**. This distal adaptation recaptures the majority of water initially held by the luminal bicarbonate, causing the overall diuretic volume effect to drop off quickly over time.
- **2. Why do these agents leave the patient with highly alkaline urine but a systemic hyperchloremic metabolic acidosis (NAGMA)?**
  *Explanation:* Because downstream segments adapt by reabsorbing NaCl instead of bicarbonate, you are left with a persistent, elevated alkalinity of the urine. Systemically, the heavy loss of the $HCOO_3^-$ base is balanced by increased bodily retention of the chloride ($Cl^-$) anion to preserve electrical neutrality, causing a **Non-Anion Gap Metabolic Acidosis (NAGMA)**.
- **3. Why does blocking bicarbonate reabsorption upstream cause severe hypokalemia downstream?**
  *Explanation:* Soluble bicarbonate ($NaHCO_3$) requires a cation companion to be excreted in urine. Since sodium is aggressively scavenged and saved by distal transporters, the luminal bicarbonate is forced to pair primarily with **potassium** for excretion, leading to severe renal potassium wasting.

***Section Summary Focus:*** *In short, the structural hallmark of chronic carbonic anhydrase inhibitor use is the clinical development of a* ***hyperchloremic metabolic acidosis associated with profound hypokalemia****, accompanied by a progressive loss of diuretic efficacy as you are left primarily with an alkaline urine profile.*

## THERAPEUTIC USES [3]

- **1. Urinary Alkalization:** Markedly elevates urine pH to enhance the ionization and rapid clearance of acidic drugs and toxic agents.
- **2. Secretion Volume Reduction (Glaucoma & ICP):** Attenuates bicarbonate-dependent secretory processes to decrease **intraocular pressure** (acute glaucoma management) and reduce **cerebrospinal fluid (CSF)** production (managing increased intracranial pressure / hydrocephalus).
- **3. Therapeutic Induction of Metabolic Acidosis:** Intentionally induces a low-bicarbonate metabolic state used clinically for three explicit purposes:
  - **A. Correction of Metabolic Alkalosis:** Wastes systemic bicarbonate to effectively restore normal physiological pH balance.
  - **B. Adjuvant in Epilepsy:** The induced acidotic state successfully elevates the patient's seizure threshold within neural tissues.
  - **C. Acute Mountain Sickness:** The underlying metabolic acidosis triggers a compensatory respiratory drive that enhances alveolar ventilation and drastically improves arterial oxygenation at high altitudes.

## ADVERSE EFFECTS [5]

**Active Recall Mnemonic: A S K H N**

- **1. [A]cidosis:** Hyperchloremic metabolic acidosis (NAGMA) secondary to persistent renal bicarbonate wasting.
- **2. [S]tones (Calcium Phosphate Nephrolithiasis):** Accelerates kidney stone formation via a dual mechanism: (a) Calcium phosphate precipitates and is completely insoluble in alkaline urine, and (b) physiological agents that stabilize calcium phosphate solubility are basic, meaning their luminal secretion drops off in alkaline conditions.
- **3. [K]alium Loss:** Severe hypokalemia due to the absolute physiological obligation of dumping potassium alongside luminal bicarbonate anions.
- **4. [H]ypersensitivity:** Potential for causing acute systemic sulfonamide-type allergic hypersensitivity reactions.
- **5. [N]itrogen Accumulation (Hyperammonemia):** High urine alkalinity completely neutralizes the standard **ion-trapping mechanism** needed to pull dangerous ammonia ($NH_3 \rightarrow NH_4^+$) into the urine lumen, resulting in systemic ammonia accumulation and toxicity.

# Study Summary: Loop Diuretics

A concise, high-yield guide to mechanisms, characteristics, side effects, and therapeutic uses.

## Overview of Loop Diuretics

Loop diuretics are the most potent class of diuretics. They are classified based on their chemical structures:

- **Sulfonamide Derivatives:** Furosemide, Bumetanide, and Torsemide.
- **Phenoxyacetic Acid Derivatives:** Ethacrynic acid.

## 1. Mechanism of Action (MOA)

- **NKCC Cotransporter Inhibition:** They primarily inhibit the $Na^+/K^+/2Cl^-$ (*NKCC2*) cotransporter in the **thick ascending limb of the Loop of Henle**.
  - This leads to a significant decrease in the reabsorption of $Na^+$, $K^+$, and $Cl^-$.
  - Because $Mg^{2+}$ and $Ca^{2+}$ reabsorption is normally driven by the positive electrical gradient generated by $K^+$ recycling, inhibiting this transporter also stops $Mg^{2+}$ and $Ca^{2+}$ reabsorption.
- **Renal Prostaglandin (PG) Stimulation:** They stimulate the release of renal prostaglandins, inducing **renal vasodilation**.
  - This increases renal perfusion, making them highly valuable in managing **Acute Kidney Failure (AKF)**.
  - **Rapid Symptom Relief:** This prostaglandin-mediated venodilation rapidly improves Heart Failure (HF) and pulmonary congestion symptoms *before* a noticeable increase in diuresis (urine output) even occurs.
- **Carbonic Anhydrase Inhibition:** Furosemide and Bumetanide possess secondary, weak inhibitory activity against carbonic anhydrase enzymes.

## 2. Drug Characteristics & Pharmacokinetics

- **No "Ceiling" Effect:** They are high-ceiling diuretics, meaning their efficacy continues to increase proportionally with the dose. They exhibit no tolerance ceiling and are the most potent diuretics available.
- **Absorption & Binding:** They are rapidly absorbed and can be administered orally (**PO**). They are extensively bound to plasma proteins.
- **Metabolism:** Furosemide and Ethacrynic acid are partially metabolized by the body.
- **Extended Duration:** Torsemide produces an active metabolite with a half-life ($t_{1/2}$) longer than the parent compound, giving it a prolonged duration of action.

## 3. Adverse Effects (The "3H, 1O" Mnemonic)

1. **Hypokalemic Metabolic Alkalosis:** Induced by increased sodium delivery to the downstream distal nephron, which accelerates $K^+$ and $H^+$ excretion.
    - *Secondary Effect:* **Hyperglycemia** can occur because hypokalemia directly inhibits insulin release from pancreatic beta cells.
2. **Electrolyte & Volume Depletion:** Profound **Hypomagnesemia**, **Hypokalemia**, and **Hyponatremia**, accompanied by severe volume loss and dehydration.
3. **Hyperuricemia:** Increased uric acid retention in the blood, which can trigger **acute gouty attacks**.
4. **Otoxicity:** Dose-related ototoxicity that can result in transient or permanent **deafness** (notably higher risk with Ethacrynic acid).

## 4. Therapeutic Uses

- **Congestive Heart Failure (CHF):** Used to rapidly reduce acute pulmonary edema and peripheral edema associated with heart failure.
- **Acute Kidney Failure (AKF):** Used to optimize and maintain renal blood flow and turn oliguric renal failure into non-oliguric states due to their vasodilatory action.
- **Hypercalcemia:** Utilized to lower dangerously high blood calcium levels by forcing renal calcium excretion.
- **Hyperkalemia:** Used as a first-line pharmacotherapy to lower critically high serum potassium levels by significantly enhancing renal $K^+$ excretion.
- **Forced Diuresis for Toxicity:** Used to accelerate the renal elimination of reabsorbable toxins and specific anions (such as Bromide [$Br^-$] and Fluoride [$F^-$]).

> 🚨 **Critical Clinical Note:** To prevent severe dehydration and fatal electrolyte imbalances during forced diuresis, a **saline solution must be co-administered** to continuously replace lost fluids and electrolytes.

# Thiazide Diuretics

High-Yield Active Recall Board & Instructional Summary

## 1. Mechanism of Action & Key Physiology

Total: 3

1. **Inhibition of the $Na^+/Cl^-$ Symporter:** They directly block the $Na^+/Cl^-$ cotransporter (NCX) in the luminal membrane of the **Distal Convoluted Tubule (DCT)**, preventing the reabsorption of sodium and chloride.

   > **Sub-point (Compensatory Mechanism):**
   > The resulting sodium and volume depletion triggers a systemic compensatory response that **increases $Na^+$ and water reabsorption in the Proximal Convoluted Tubule (PCT)**. This is precisely why they treat **Nephrogenic Diabetes Insipidus**—by pulling more fluid back early in the PCT, less fluid reaches downstream non-functional ducts, reducing overall polyuria.

2. **Enhanced Calcium Reabsorption:** Unlike loop diuretics, thiazides increase $Ca^{2+}$ reabsorption. Blocking apical entry drops intracellular $Na^+$, which forces the basolateral **$Na^+/Ca^{2+}$ exchanger** to work faster—pumping $Na^+$ into the cell and pulling $Ca^{2+}$ out of the tubular fluid back into the blood.

3. **Carbonic Anhydrase Inhibition:** Along with their primary channel blockade, they possess significant, secondary **carbonic anhydrase inhibition** activity.

## 2. Drug Classification

Total: 5

### CLASSIC THIAZIDES (3 DRUGS)

1. **Hydrochlorothiazide (HCTZ):** The classic, widely used oral prototype agent of this class.
2. **Chlorothiazide:** Notable because it is the **only thiazide available for parenteral (IV) use**, though it has very limited solubility.
3. **Chlorthalidone:** A thiazide-like agent that is slowly absorbed, giving it a **distinctly long duration of action**.

### NEWER THIAZIDE-LIKE DRUGS (2 DRUGS)

1. **Indapamide:** Unique because it is primarily **excreted through the biliary system**, making it a safer choice for patients with renal insufficiency.
2. **Metolazone:** An extremely potent thiazide-like diuretic that **remains effective even in patients with advanced renal failure** (low GFR).

## 3. General Pharmacokinetic & Chemical Characteristics

Total: 2

1. **Sulfonamide Moiety (All Thiazides & Thiazide-Like Drugs):** Every drug in this class contains a sulfonamide chemical group. Because of this, they can all trigger hypersensitivity allergic reactions, manifesting predominantly as **allergic dermatitis** (which can be severe) and **photosensitivity** skin rashes.
2. **Active Tubular Secretion via OATs:** All thiazides are highly protein-bound and cannot be filtered freely at the glomerulus. Instead, they are all **actively secreted into the tubular lumen via Organic Acid Transporters (OATs)** to reach their site of action. Because they utilize this pathway, they directly **compete with uric acid secretion**, which can ultimately lead to hyperuricemia.

## 4. Adverse Effects & Complications

Total: 9

### ELECTROLYTE & METABOLIC DISTURBANCES (5 ITEMS)

1. **Hypokalemic Metabolic Alkalosis:** Increased $Na^+$ delivery to the downstream collecting duct accelerates aldosterone-mediated exchange, causing excessive **$K^+$ and $H^+$ secretion** into the urine.
2. **Hyponatremia:** Severe drops in sodium can occur due to a combination of renal $Na^+$ loss and ADH-driven water retention.
3. **Hyperuricemia:** Secondary to the competition for secretion via the Organic Acid Transporters (OATs) as detailed in the kinetics section.
4. **Hyperglycemia:** Hypokalemia directly **impairs insulin release** from pancreatic beta cells, causing elevated blood glucose.
5. **Hyperlipidemia:** Can trigger mild, transient elevations in total serum cholesterol and LDL levels.

### ALLERGIC & SYSTEMIC SIDE EFFECTS (4 ITEMS)

1. **Allergic Dermatitis:** Hypersensitivity skin reactions ranging from standard rashes to severe dermatological forms due to the sulfonamide structure.
2. **Photosensitivity:** Heightened skin sensitivity and rapid rash development upon exposure to direct sunlight.
3. **Weakness & Fatigue:** Common general systemic complaints reported by patients on daily therapy.
4. **Impotence:** Sexual dysfunction is a well-documented clinical side effect that can impact long-term compliance.

## 5. Therapeutic Uses

Total: 4

1. **Hypertension:** Used as a foundational, first-line clinical agent for managing primary hypertension.
2. **Edema Management:** Indicated for fluid retention and volume overload stemming from **mild-to-moderate congestive heart failure (CHF)**, or **hepatic and renal insufficiency**.
3. **Nephrolithiasis:** Highly effective for patients with recurrent calcium oxalate kidney stones; increasing renal $Ca^{2+}$ reabsorption drastically **lowers calcium concentrations in the urine**, preventing stone crystallization.
4. **Nephrogenic Diabetes Insipidus:** Utilized counterintuitively to decrease total urine volume via the compensatory PCT reabsorption mechanism.

# Potassium-Sparing Diuretics

High-Yield Active Recall Board & Instructional Summary

## 1. Mechanism of Action & Key Physiology

Total: 2

1. **Physiological Baseline (Aldosterone & ENaC Action):** Aldosterone normally binds to intracellular mineralocorticoid receptors in the principal cells of the **late distal tubule and collecting duct**. This upregulates the activity and expression of **Epithelial Sodium Channels (ENaCs)** on the apical membrane.

   > **Net Normal Effect:**
   >
   > ENaCs facilitate sodium ($Na^+$) reabsorption. This leaves a net negative charge in the lumen, which electrically drives potassium ($K^+$) and hydrogen ($H^+$) excretion into the urine.

2. **The Two Diuretic Blockade Pathways:** Both classes block this pathway to check down sodium reabsorption while conserving downstream ions.
   - **Aldosterone Receptor Antagonists:** **Spironolactone** and **Eplerenone** competitively block the intracellular mineralocorticoid receptor, stopping aldosterone from upregulating ENaC production.
   - **Direct ENaC Blockers:** **Amiloride** and **Triamterene** directly plug and block the apical ENaC channels themselves, functioning completely independently of aldosterone.

## 2. Drug Classification & Specific Pharmacokinetics

Total: 4

### GROUP 1: ALDOSTERONE RECEPTOR ANTAGONISTS (2 ITEMS)

1. **Spironolactone:** Undergoes extensive plasma protein binding and significant **enterohepatic cycling**. It is metabolized by the body into **canrenone**, which is its highly active metabolite.

   > **Sub-point (Hepatic Caution):**
   > Due to its intense hepatic metabolism and cycling, you must be cautious to **reduce the dose in patients with hepatic diseases**.

2. **Eplerenone:** A newer, highly selective receptor antagonist.

   > **Sub-point (Drug Interactions):**
   > It is heavily metabolized via the CYP3A4 pathway. Strong inhibitors like **ketoconazole** and **itraconazole** will significantly increase eplerenone blood levels.

### GROUP 2: DIRECT ENAC BLOCKERS (2 ITEMS)

1. **Amiloride:** Notable because it is **excreted completely unchanged in the urine**. It features a distinctly longer half-life compared to triamterene.
2. **Triamterene:** Unlike amiloride, it is actively **metabolized by the liver** and possesses a much **shorter half-life**.

## 3. General Pharmacokinetic & Chemical Characteristics

Total: 1

1. **Prostaglandin Dependence:** The therapeutic diuretic action of **both types** of potassium-sparing diuretics depends directly on intact **prostaglandin synthesis**.

## 4. Adverse Effects & Complications

Total: 3

1. **Hyperkalemia & Metabolic Acidosis (Shared):** Inhibiting $Na^+$ reabsorption at the collecting duct prevents the negative lumen potential from pulling $K^+$ and $H^+$ out. This causes systemic retention of both ions, potentially causing dangerous hyperkalemia and metabolic acidosis.

> **High-Risk Triggers:**
> The risk heavily intensifies in patients with **renal failure**, or when combined with other potassium-elevating drugs like **NSAIDs, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), or Beta-blockers**.

2. **Anti-Androgenic Toxicity (Spironolactone-Specific):** Due to its non-selective affinity for other steroid receptors, it frequently causes **gynecomastia, impotence, and benign prostatic hyperplasia (BPH)**.

> **The Eplerenone Exception:**
> **These endocrine side effects are NOT seen with eplerenone** due to its advanced selectivity for the mineralocorticoid receptor alone.

3. **The "CAN IGP" Profile (Triamterene-Specific):** Triamterene carries a highly specific cluster of toxicities that map perfectly to the letter-for-letter mnemonic:

> **C** – **Cramps** (Specifically, painful leg cramps)
> **A** – **Azotemia**
> **N** – **Nephrolithiasis** (Kidney stones formed by the precipitation of the drug crystals)
> **I** – **Interstitial nephritis** (Which can progress directly into **Acute Renal Failure**)
> **G** – **Glucose intolerance**
> **P** – **Photosensitivity**

## 5. Therapeutic Uses

Total: 3

1. **Mineralocorticoid Excess Release States:** Indicated for states of excessive aldosterone release, whether it is **primary** (Conn's syndrome), **secondary** (fluid shifts in heart failure or liver cirrhosis), or **ectopic** production.

2. **Diuretic Conjunction Therapy:** Co-prescribed alongside potassium-wasting diuretics (loops or thiazides) specifically to **reduce urinary potassium loss** and maintain homeostasis.

3. **Hypokalemia:** Used effectively as a direct clinical treatment to safely correct existing low potassium levels.

# RENAL PHARMACOLOGY SUMMARY

*High-Yield Concept Retrieval Sheets*

## 1. Osmotic Diuretics

Total: [4] Concepts

### PHARMACOKINETICS & AGENTS [3]

- **1. Key Examples: Mannitol** is the most commonly used agent. Others include Urea, Glycerin, and Isosorbide.
- **2. Route of Administration:** Must be given **intravenously (IV)**. If administered orally, they remain unabsorbed in the GI tract and cause osmotic diarrhea.
- **3. Clearance Profile:** They undergo zero metabolism. They are freely filtered at the glomerulus and are **completely non-reabsorbable** by the renal tubules.

### MECHANISMS OF ACTION (MOA) [2]

- **1. Biphase Fluid & Electrolyte Shift:**
  - *In the blood:* They initially draw intracellular fluid into the vascular space, causing **dilutional hyponatremia**.
  - *In the nephron:* Once filtered into the **proximal tubule, descending loop of Henle, and collecting tubule**, they lock water in the lumen. This profound water diuresis ultimately leaves behind concentrated serum, causing **hypernatremia** and **hyperkalemia**.
- **2. Vascular Hemodynamics:** They stimulate renal **prostaglandin synthesis**, which dilates renal vasculature and increases total **renal blood flow**.

### THERAPEUTIC USES [4]

- **1. Pigment-Induced Acute Renal Failure:** Used to maintain urine volume and flush out high pigment loads, specifically **myoglobin** (from rhabdomyolysis) or **hemoglobin** (from hemolysis).
- **2. Intracranial Pressure (ICP) Reduction:** Draws fluid out of cerebral tissues to reduce brain swelling.
- **3. Intraocular Pressure (IOP) Reduction:** Decreases fluid pressure in the eye during acute glaucoma.
- **4. Refractory Edema (Severe Sodium Retention):** Used when patients have massive aldosterone release or severe dehydration where traditional diuretics fail.
  *Clinical Implication:* Their success here lies in the fact that their diuresis is entirely **independent of blocking sodium reabsorption**.

## 2. ADH Receptor Antagonists

Total: [2] Concepts

### AGENT CLASSIFICATION [2]

- **1. Selective Antagonists: Conivaptan** (blocks the ADH receptors directly).
- **2. Non-Selective/Indirect Agents: Lithium** and **Demeclocycline** (rarely used due to side effect profiles).

### MECHANISM OF ACTION (MOA) [1]

> **1. The Antidiuretic Signaling Cascade Blockade:** These agents competitively bind to and block ADH ($V_2$) receptors on the basolateral membrane of the collecting duct cells; this directly prevents the intracellular activation of adenylate cyclase and the subsequent rise of **cAMP**, which ultimately halts the trafficking and insertion of **aquaporin-2 channels** onto the apical (luminal) membrane, leaving the collecting duct completely impermeable to water.

### THERAPEUTIC USES [1]

- **1. SIADH Management:** Primarily indicated for the **Syndrome of Inappropriate ADH Secretion** to correct water retention and hyponatremia.

### ADVERSE EFFECTS [3]

- **1. Nephrogenic Diabetes Insipidus:** Caused by the direct, intended, but exaggerated blockade of ADH action in the kidney.
- **2. Systemic Free Water Loss:** Manifests as extreme **thirst**, **dry mouth**, and **hypernatremia** (due to excess water loss over sodium).
- **3. Volume Depletion:** Can trigger systemic **hypotension** due to excessive diuresis.